HB2196 mandates coverage for intravenous immunoglobulin therapy for pediatric autoimmune neuropsychiatric disorders.

HB2196 requires health carriers to cover three monthly courses of intravenous immunoglobulin therapy for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections or pediatric acute-onset neuropsychiatric syndrome. It prohibits denial of coverage based on prior treatment, diagnosis under a different name, or out-of-state availability. The bill also mandates clinical reevaluation every three months and requires adherence to treatment guidelines based on positive patient outcomes.

HB2196 mandates coverage for intravenous immunoglobulin therapy for pediatric autoimmune neuropsychiatric disorders.

HB2196 requires health carriers to cover three monthly courses of intravenous immunoglobulin therapy for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections or pediatric acute-onset neuropsychiatric syndrome. It prohibits denial of coverage based on prior treatment, diagnosis under a different name, or out-of-state availability. The bill also mandates clinical reevaluation every three months and requires adherence to treatment guidelines based on positive patient outcomes.